Tigecycline: A new glycylcycline for treatment of serious infections
Tigecycline: A new glycylcycline for treatment of serious infections
复制标题
DOI：
10.1086/431672
复制
发表时间：
2005-09-01
影响因子：
11.8
通讯作者：
Noskin, GA
中科院分区：
文献类型：
--
作者：
Noskin, GA
替加环素是一种治疗严重感染的新型半合成甘环素。在甘环素中，替加环素是研究最多的，似乎有望成为一种新的抗菌剂，可以作为多种严重细菌感染患者的单药治疗。对于严重感染的患者，最初选择广谱抗生素的经验性治疗是至关重要的，如果选择不当，可能会对患者产生不良后果。替加环素已被设计用于克服细菌之间的许多现有耐药机制，并赋予广泛的抗生素覆盖范围，以对抗万古霉素耐药肠球菌，耐甲氧西林金黄色葡萄球菌和许多种多重耐药革兰氏阴性细菌。替加环素在人类临床2期研究中已经证明了其有效性和良好的耐受性，这就需要在更大规模的研究中进一步评估替加环素治疗许多适应症，包括复杂的皮肤和皮肤结构感染、复杂的腹腔感染和下呼吸道感染。
Tigecycline is a new semisynthetic glycylcycline for the treatment of serious infections. Of the glycylcyclines, tigecycline is the most studied and appears to hold promise as a new antimicrobial agent that can be administered as monotherapy to patients with many types of serious bacterial infections. For patients with serious infections, the initial choice for empirical therapy with broad-spectrum antibiotics is crucial, and, if the choice is inappropriate, it may have adverse consequences for the patient. Tigecycline has been designed to overcome many existing mechanisms of resistance among bacteria and confers broad antibiotic coverage against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and many species of multidrug-resistant gram-negative bacteria. Tigecycline has been efficacious and well tolerated in human clinical phase 2 studies, which warranted further evaluation of tigecycline in larger studies for treatment of many indications, including complicated skin and skin-structure infections, complicated intra-abdominal infections, and infections of the lower respiratory tract.